Activating Compound | Comment | Organism | Structure |
---|---|---|---|
forskolin | catalytic heterodimer VC1-IIC2 | Rattus norvegicus | |
forskolin | catalytic heterodimer VC1-IIC2 | Canis lupus familiaris | |
Galphas | catalytic heterodimer VC1-IIC2 | Rattus norvegicus | |
Galphas | catalytic heterodimer VC1-IIC2 | Canis lupus familiaris |
Crystallization (Comment) | Organism |
---|---|
crystal structures of catalytic domains VC1-IIC2 bound to 2'(3')-O-(N-methylanthraniloyl)-GTP, 2'(3')-O-(N-methylanthraniloyl)-ATP, and 2',3'-(2,4,6-trinitrophenyl)-ATP, at 2.9 to 3.3 A resolution, inhibitors reside in the same binding pocket in the VC1-IIC2 protein complex, but there are substantial differences in interactions of base, fluorophore, and polyphosphate chain of the inhibitors with mAC | Rattus norvegicus |
crystal structures of catalytic domains VC1-IIC2 bound to 2'(3')-O-(N-methylanthraniloyl)-GTP, 2'(3')-O-(N-methylanthraniloyl)-ATP, and 2',3'-(2,4,6-trinitrophenyl)-ATP, at 2.9 to 3.3 A resolution, inhibitors reside in the same binding pocket in the VC1-IIC2 protein complex, but there are substantial differences in interactions of base, fluorophore, and polyphosphate chain of the inhibitors with mAC | Canis lupus familiaris |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
2'(3')-O-(N-methylanthraniloyl)-ATP | catalytic heterodimer VC1-IIC2 | Canis lupus familiaris | |
2'(3')-O-(N-methylanthraniloyl)-ATP | catalytic heterodimer VC1-IIC2 | Rattus norvegicus | |
2'(3')-O-(N-methylanthraniloyl)-GTP | catalytic heterodimer VC1-IIC2 | Canis lupus familiaris | |
2'(3')-O-(N-methylanthraniloyl)-GTP | catalytic heterodimer VC1-IIC2, incompletely defined structure 2'- or 3'-substituted nucleoside triphosphate | Rattus norvegicus | |
2',3'-bis[(2-(N-methylanthraniloyl)amino)ethyl-carbamoyl]-ATP | - |
Canis lupus familiaris | |
2',3'-bis[(2-(N-methylanthraniloyl)amino)ethyl-carbamoyl]-ATP | catalytic heterodimer VC1-IIC2 | Rattus norvegicus | |
2',3'-di[(2-(N-methylanthraniloyl)amino)ethyl-carbamoyl]-ATP | catalytic heterodimer VC1-IIC2 | Canis lupus familiaris | |
2',3'-di[(2-(N-methylanthraniloyl)amino)ethyl-carbamoyl]-ATP | - |
Rattus norvegicus | |
2',3'-O-(2,4,6-trinitrophenyl)-ADP | catalytic heterodimer VC1-IIC2 | Canis lupus familiaris | |
2',3'-O-(2,4,6-trinitrophenyl)-ADP | catalytic heterodimer VC1-IIC2 | Rattus norvegicus | |
2',3'-O-(2,4,6-trinitrophenyl)-AMP | catalytic heterodimer VC1-IIC2 | Canis lupus familiaris | |
2',3'-O-(2,4,6-trinitrophenyl)-AMP | catalytic heterodimer VC1-IIC2 | Rattus norvegicus | |
2',3'-O-(2,4,6-trinitrophenyl)-ATP | catalytic heterodimer VC1-IIC2 | Canis lupus familiaris | |
2',3'-O-(2,4,6-trinitrophenyl)-ATP | catalytic heterodimer VC1-IIC2 | Rattus norvegicus | |
2',3'-O-(2,4,6-trinitrophenyl)-CTP | catalytic heterodimer VC1-IIC2 | Canis lupus familiaris | |
2',3'-O-(2,4,6-trinitrophenyl)-CTP | catalytic heterodimer VC1-IIC2, incompletely defined structure 2'- or 3'-substituted nucleoside triphosphate | Rattus norvegicus | |
2',3'-O-(2,4,6-trinitrophenyl)-GDP | catalytic heterodimer VC1-IIC2 | Canis lupus familiaris | |
2',3'-O-(2,4,6-trinitrophenyl)-GDP | catalytic heterodimer VC1-IIC2 | Rattus norvegicus | |
2',3'-O-(2,4,6-trinitrophenyl)-GTP | catalytic heterodimer VC1-IIC2 | Canis lupus familiaris | |
2',3'-O-(2,4,6-trinitrophenyl)-GTP | catalytic heterodimer VC1-IIC2 | Rattus norvegicus | |
2',3'-O-(2,4,6-trinitrophenyl)-UTP | catalytic heterodimer VC1-IIC2 | Canis lupus familiaris | |
2',3'-O-(2,4,6-trinitrophenyl)-UTP | catalytic heterodimer VC1-IIC2 | Rattus norvegicus | |
8-[(4-(N-methylanthraniloyl)amino)butyl]amino-ATP | catalytic heterodimer VC1-IIC2 | Canis lupus familiaris | |
8-[(4-(N-methylanthraniloyl)amino)butyl]amino-ATP | catalytic heterodimer VC1-IIC2 | Rattus norvegicus | |
8-[(6-(N-methylanthraniloyl)amino)hexyl]-amino-ATP | catalytic heterodimer VC1-IIC2 | Canis lupus familiaris | |
8-[(6-(N-methylanthraniloyl)amino)hexyl]-amino-ATP | catalytic heterodimer VC1-IIC2 | Rattus norvegicus | |
N6-[6-((N-methylanthraniloyl)amino)hexyl]-ATP | catalytic heterodimer VC1-IIC2 | Canis lupus familiaris | |
N6-[6-((N-methylanthraniloyl)amino)hexyl]-ATP | catalytic heterodimer VC1-IIC2 | Rattus norvegicus |
Metals/Ions | Comment | Organism | Structure |
---|---|---|---|
Mn2+ | catalytic heterodimer VC1-IIC2 | Rattus norvegicus | |
Mn2+ | catalytic heterodimer VC1-IIC2 | Canis lupus familiaris |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Canis lupus familiaris | - |
- |
- |
Rattus norvegicus | - |
- |
- |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
ATP | catalytic heterodimer VC1-IIC2 | Rattus norvegicus | 3',5'-cAMP + diphosphate | - |
? | |
ATP | catalytic heterodimer VC1-IIC2 | Canis lupus familiaris | 3',5'-cAMP + diphosphate | - |
? |
Synonyms | Comment | Organism |
---|---|---|
mAC | C1 domain of type V mAC (VC1) | Canis lupus familiaris |
mAC | C2 domain of type II mAC (IIC2) | Rattus norvegicus |
membrane adenylyl cyclase | - |
Rattus norvegicus |
membrane adenylyl cyclase | - |
Canis lupus familiaris |
Ki Value [mM] | Ki Value maximum [mM] | Inhibitor | Comment | Organism | Structure |
---|---|---|---|---|---|
0.000011 | - |
2'(3')-O-(N-methylanthraniloyl)-ATP | VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas | Rattus norvegicus | |
0.000011 | - |
2'(3')-O-(N-methylanthraniloyl)-ATP | VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas | Canis lupus familiaris | |
0.000014 | - |
2'(3')-O-(N-methylanthraniloyl)-GTP | VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas | Rattus norvegicus | |
0.000014 | - |
2'(3')-O-(N-methylanthraniloyl)-GTP | VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas | Canis lupus familiaris | |
0.000081 | - |
2',3'-O-(2,4,6-trinitrophenyl)-ATP | VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas | Rattus norvegicus | |
0.000081 | - |
2',3'-O-(2,4,6-trinitrophenyl)-ATP | VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas | Canis lupus familiaris | |
0.000083 | - |
2',3'-O-(2,4,6-trinitrophenyl)-GTP | VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas | Rattus norvegicus | |
0.000083 | - |
2',3'-O-(2,4,6-trinitrophenyl)-GTP | VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas | Canis lupus familiaris | |
0.000092 | - |
2',3'-O-(2,4,6-trinitrophenyl)-UTP | VC1-IIC2 in the presence of 0.1 mM forskolin | Rattus norvegicus | |
0.000092 | - |
2',3'-O-(2,4,6-trinitrophenyl)-UTP | VC1-IIC2 in the presence of 0.1 mM forskolin | Canis lupus familiaris | |
0.000092 | - |
2',3'-O-(2,4,6-trinitrophenyl)-UTP | VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas | Rattus norvegicus | |
0.000092 | - |
2',3'-O-(2,4,6-trinitrophenyl)-UTP | VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas | Canis lupus familiaris | |
0.0001 | - |
2',3'-O-(2,4,6-trinitrophenyl)-ATP | VC1-IIC2 in the presence of 0.1 mM forskolin | Rattus norvegicus | |
0.0001 | - |
2',3'-O-(2,4,6-trinitrophenyl)-ATP | VC1-IIC2 in the presence of 0.1 mM forskolin | Canis lupus familiaris | |
0.00011 | - |
2'(3')-O-(N-methylanthraniloyl)-ATP | VC1-IIC2 in the presence of 0.1 mM forskolin | Rattus norvegicus | |
0.00011 | - |
2'(3')-O-(N-methylanthraniloyl)-ATP | VC1-IIC2 in the presence of 0.1 mM forskolin | Canis lupus familiaris | |
0.00011 | - |
2',3'-O-(2,4,6-trinitrophenyl)-CTP | VC1-IIC2 in the presence of 0.1 mM forskolin | Rattus norvegicus | |
0.00011 | - |
2',3'-O-(2,4,6-trinitrophenyl)-CTP | VC1-IIC2 in the presence of 0.1 mM forskolin | Canis lupus familiaris | |
0.00013 | - |
2'(3')-O-(N-methylanthraniloyl)-GTP | VC1-IIC2 in the presence of 0.1 mM forskolin | Rattus norvegicus | |
0.00013 | - |
2'(3')-O-(N-methylanthraniloyl)-GTP | VC1-IIC2 in the presence of 0.1 mM forskolin | Canis lupus familiaris | |
0.00031 | - |
2',3'-O-(2,4,6-trinitrophenyl)-CTP | VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas | Rattus norvegicus | |
0.00031 | - |
2',3'-O-(2,4,6-trinitrophenyl)-CTP | VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas | Canis lupus familiaris | |
0.00043 | - |
2',3'-O-(2,4,6-trinitrophenyl)-GTP | VC1-IIC2 in the presence of 0.1 mM forskolin | Rattus norvegicus | |
0.00043 | - |
2',3'-O-(2,4,6-trinitrophenyl)-GTP | VC1-IIC2 in the presence of 0.1 mM forskolin | Canis lupus familiaris | |
0.0013 | - |
2',3'-O-(2,4,6-trinitrophenyl)-ADP | VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas | Rattus norvegicus | |
0.0013 | - |
2',3'-O-(2,4,6-trinitrophenyl)-ADP | VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas | Canis lupus familiaris | |
0.002 | - |
2',3'-O-(2,4,6-trinitrophenyl)-ADP | VC1-IIC2 in the presence of 0.1 mM forskolin | Rattus norvegicus | |
0.002 | - |
2',3'-O-(2,4,6-trinitrophenyl)-ADP | VC1-IIC2 in the presence of 0.1 mM forskolin | Canis lupus familiaris | |
0.0055 | - |
2',3'-bis[(2-(N-methylanthraniloyl)amino)ethyl-carbamoyl]-ATP | VC1-IIC2 in the presence of 0.1 mM forskolin | Rattus norvegicus | |
0.0055 | - |
2',3'-bis[(2-(N-methylanthraniloyl)amino)ethyl-carbamoyl]-ATP | VC1-IIC2 in the presence of 0.1 mM forskolin | Canis lupus familiaris | |
0.0067 | - |
2',3'-di[(2-(N-methylanthraniloyl)amino)ethyl-carbamoyl]-ATP | VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas | Rattus norvegicus | |
0.0067 | - |
2',3'-di[(2-(N-methylanthraniloyl)amino)ethyl-carbamoyl]-ATP | VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas | Canis lupus familiaris | |
0.0081 | - |
2',3'-O-(2,4,6-trinitrophenyl)-GDP | VC1-IIC2 in the presence of 0.1 mM forskolin | Rattus norvegicus | |
0.0081 | - |
2',3'-O-(2,4,6-trinitrophenyl)-GDP | VC1-IIC2 in the presence of 0.1 mM forskolin | Canis lupus familiaris | |
0.0094 | - |
2',3'-O-(2,4,6-trinitrophenyl)-GDP | VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas | Rattus norvegicus | |
0.0094 | - |
2',3'-O-(2,4,6-trinitrophenyl)-GDP | VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas | Canis lupus familiaris | |
0.0094 | - |
N6-[6-((N-methylanthraniloyl)amino)hexyl]-ATP | VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas | Rattus norvegicus | |
0.0094 | - |
N6-[6-((N-methylanthraniloyl)amino)hexyl]-ATP | VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas | Canis lupus familiaris | |
0.0094 | - |
8-[(4-(N-methylanthraniloyl)amino)butyl]amino-ATP | VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas | Rattus norvegicus | |
0.0094 | - |
8-[(4-(N-methylanthraniloyl)amino)butyl]amino-ATP | VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas | Canis lupus familiaris | |
0.01 | - |
8-[(4-(N-methylanthraniloyl)amino)butyl]amino-ATP | VC1-IIC2 in the presence of 0.1 mM forskolin | Rattus norvegicus | |
0.01 | - |
8-[(4-(N-methylanthraniloyl)amino)butyl]amino-ATP | VC1-IIC2 in the presence of 0.1 mM forskolin | Canis lupus familiaris | |
0.011 | - |
N6-[6-((N-methylanthraniloyl)amino)hexyl]-ATP | VC1-IIC2 in the presence of 0.1 mM forskolin | Rattus norvegicus | |
0.011 | - |
N6-[6-((N-methylanthraniloyl)amino)hexyl]-ATP | VC1-IIC2 in the presence of 0.1 mM forskolin | Canis lupus familiaris | |
0.017 | - |
2',3'-O-(2,4,6-trinitrophenyl)-AMP | VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas | Rattus norvegicus | |
0.017 | - |
2',3'-O-(2,4,6-trinitrophenyl)-AMP | VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas | Canis lupus familiaris | |
0.021 | - |
2',3'-O-(2,4,6-trinitrophenyl)-AMP | VC1-IIC2 in the presence of 0.1 mM forskolin | Rattus norvegicus | |
0.021 | - |
2',3'-O-(2,4,6-trinitrophenyl)-AMP | VC1-IIC2 in the presence of 0.1 mM forskolin | Canis lupus familiaris | |
0.058 | - |
8-[(6-(N-methylanthraniloyl)amino)hexyl]-amino-ATP | VC1-IIC2 in the presence of 0.1 mM forskolin | Rattus norvegicus | |
0.058 | - |
8-[(6-(N-methylanthraniloyl)amino)hexyl]-amino-ATP | VC1-IIC2 in the presence of 0.1 mM forskolin | Canis lupus familiaris | |
0.1 | - |
8-[(6-(N-methylanthraniloyl)amino)hexyl]-amino-ATP | VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas | Rattus norvegicus | |
0.1 | - |
8-[(6-(N-methylanthraniloyl)amino)hexyl]-amino-ATP | VC1-IIC2 in the presence of 0.1 mM forskolin and GTPgammaS-activated Galphas | Canis lupus familiaris |